Huaota Biopharm develops high-quality biological drugs for the global market.
Shanghai Huaota Biopharm is a wholly owned subsidiary of Huahai Pharmaceuticals and was established in September 2013. Huaota is dedicated to develop high quality biological drugs for global market to meet the demand of availability and affordability for high-end biological products from global patients. Huaota employs the state-of-the-art biopharmaceutical manufacturing technology and equipments to build production line meeting the GMP requirement from CFDA, US FDA and EU EMA. Huaota currently has one 200L and one 1000L disposable bioreactor and two fill-and-finish lines to support both prefilled syringe and vial filling.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 30, 2017 | Angel | ¥3M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Huahai Yaoye | — | Angel |